Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the specified deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [4]. - It is claimed that the overstated regulatory prospects and clinical data could significantly negatively impact Biohaven's business and financial condition once revealed [4]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading throughout the Class Period, leading to investor damages when the truth emerged [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's product candidates and their regulatory prospects [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 24, 2023, to May 14, 2025 [3]. - Allegations include that Biohaven overstated the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the efficacy of BHV-7000 for bipolar disorder [3]. - It is claimed that these misrepresentations are likely to have a significant negative impact on Biohaven's business and financial condition once revealed [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 12, 2025, to potentially be appointed as lead plaintiffs [4]. - Registration will provide shareholders with portfolio monitoring software for status updates throughout the case [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these inaccuracies would likely have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, and the lead plaintiff deadline is September 12, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by the lead plaintiff deadline to serve as lead plaintiff [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated claims about the drug's prospects likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed [4] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading throughout the class period [4]

Core Viewpoint - Biohaven's stock experienced a significant increase of over 6% following positive regulatory news from the FDA regarding its New Drug Application for troriluzole, outperforming the S&P 500 index's 1.5% gain on the same day [1]. Regulatory Progress - Biohaven disclosed in a filing with the SEC that the FDA informed the company that an advisory committee meeting for the New Drug Application (NDA) for troriluzole is no longer necessary [2]. - Troriluzole is aimed at treating spinocerebellar ataxia, a group of inherited neurological disorders affecting movement, and the drug's development faced initial setbacks, including the FDA's refusal to accept the filing [4]. Implications of Advisory Meeting Cancellation - The cancellation of the advisory meeting suggests that the FDA may have already made a decision regarding the NDA, although it does not guarantee a favorable outcome for Biohaven [5]. - Research indicates that approximately two-thirds of applications with canceled advisory meetings have received approval from the FDA since 2019, which explains the market's positive reaction to the news [6].

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for bipolar disorder [2]. - It is alleged that the misleading statements were likely to have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 12, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Allegations Against Biohaven - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated prospects were likely to negatively impact Biohaven's business and financial condition once revealed [4] - Investors are said to have suffered damages when the true details about the company's statements became public [4]

Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that negatively impacted investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and the efficacy of BHV-7000 for bipolar disorder, which were overstated [2]. - The complaint suggests that the revelation of these misstatements is likely to have a significant negative impact on Biohaven's business and financial condition [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The FDA has canceled the advisory committee meeting for Biohaven's core drug, trorluzole, leading to a significant pre-market stock increase of 12.3% [1] Company Summary - Biohaven, a biotech company based in New Haven, Connecticut, received priority review status from the FDA for its new drug application (NDA) for trorluzole, aimed at treating spinocerebellar ataxia, a rare neurodegenerative disease [1] - The FDA extended the review period in May to assess additional materials submitted by Biohaven in response to agency requests [1] - On August 21, the FDA notified Biohaven that the advisory committee meeting was no longer necessary for the review process [1] - Biohaven is a spin-off of Biohaven Pharmaceutical, which was acquired by Pfizer in 2022, and the company expects the FDA to make a decision on its NDA by Q4 2025 [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025, with a lead plaintiff deadline set for September 12, 2025 [1][2] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3] - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [3] Group 3: Case Allegations - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that these misrepresentations likely had a significant negative impact on Biohaven's business and financial condition once the truth was revealed [4]